He will serve jointly in the role with Susan Hunter, AusCann’s existing company secretary.
Megson joined the medical cannabis company in October 2018 and is an experienced senior executive.
The new joint company secretary has worked in both finance and operational roles for more than 25 years and has held non-executive directorships with several companies.
He holds a Bachelor of Commerce from The University of Western Australia and is a Member of the Institute of Chartered Accountants Australia and New Zealand.
AusCann is an Australian-based pharmaceutical company that aims to produce high-quality, economical and clinically validated cannabinoid medicines.
The company brings together leading expertise and operations across all aspects of the medical cannabis value chain.
This begins with cultivation and production and extends through to manufacture and distribution of products.
Last month AusCann acquired a 7,300 square metre research and development (R&D) facility in Perth, Western Australia.
The facility, which was purchased for $5.25 million, will focus on AusCann’s cannabinoid pharmaceutical product pipeline, supporting development of innovative formulations and dose forms.
AusCann will invest up to $6 million over time to customise and fit out the site for use during 2019.
The acquisition and upgrade costs will be funded from AusCann’s cash balance which was more than $40 million prior to the acquisition.